BACKGROUND: To investigate the efficacy and the adverse effects (AEs) of the electronic cigarette, we performed a systematic review of published studies. METHODS: We selected experimental and observational studies examining the efficacy (as reduction of desire to smoke and/or number of cigarettes smoked and/or quitting or as reduction of nicotine withdrawal symptoms) and the safety of EC (AEs self-reported or clinical/laboratory). The following search engines were used: PubMed, ISI Web of Knowledge and Cochrane Controlled Trials Register. RESULTS: Finally, six experimental studies and six cohort studies were included. In the prospective 12-month, randomized controlled trial, smoking reduction was documented in 22.3 and 10.3% at Weeks 12 and 52, respectively (P < 0.001 versus baseline). Moreover, two cohort studies reported a reduction in the number of cigarette/day (from 50 to 80%) after the introduction of the EC. 'Mouth and throat irritation', 'nausea', 'headache' and 'dry cough' were the most frequently AEs reported. CONCLUSIONS: The use of the EC can reduce the number of cigarettes smoked and withdrawal symptoms, but the AEs reported are mainly related to a short period of use. Long-term studies are needed to evaluate the effects of the EC usage after a chronic exposure.
BACKGROUND: To investigate the efficacy and the adverse effects (AEs) of the electronic cigarette, we performed a systematic review of published studies. METHODS: We selected experimental and observational studies examining the efficacy (as reduction of desire to smoke and/or number of cigarettes smoked and/or quitting or as reduction of nicotine withdrawal symptoms) and the safety of EC (AEs self-reported or clinical/laboratory). The following search engines were used: PubMed, ISI Web of Knowledge and Cochrane Controlled Trials Register. RESULTS: Finally, six experimental studies and six cohort studies were included. In the prospective 12-month, randomized controlled trial, smoking reduction was documented in 22.3 and 10.3% at Weeks 12 and 52, respectively (P < 0.001 versus baseline). Moreover, two cohort studies reported a reduction in the number of cigarette/day (from 50 to 80%) after the introduction of the EC. 'Mouth and throat irritation', 'nausea', 'headache' and 'dry cough' were the most frequently AEs reported. CONCLUSIONS: The use of the EC can reduce the number of cigarettes smoked and withdrawal symptoms, but the AEs reported are mainly related to a short period of use. Long-term studies are needed to evaluate the effects of the EC usage after a chronic exposure.
Authors: Allison M Glasser; Lauren Collins; Jennifer L Pearson; Haneen Abudayyeh; Raymond S Niaura; David B Abrams; Andrea C Villanti Journal: Am J Prev Med Date: 2016-11-30 Impact factor: 5.043
Authors: Ashley L Comiford; Dorothy A Rhoades; Justin D Dvorak; Kai Ding; Toral Mehta; Paul Spicer; Theodore Wagener; Mark P Doescher Journal: Public Health Rep Date: 2020-01 Impact factor: 2.792
Authors: Raman Baweja; Katherine M Curci; Jessica Yingst; Susan Veldheer; Shari Hrabovsky; Stephen J Wilson; Travis T Nichols; Thomas Eissenberg; Jonathan Foulds Journal: Addict Res Theory Date: 2015-09-02
Authors: Lamberto Manzoli; Maria Elena Flacco; Maria Fiore; Carlo La Vecchia; Carolina Marzuillo; Maria Rosaria Gualano; Giorgio Liguori; Giancarlo Cicolini; Lorenzo Capasso; Claudio D'Amario; Stefania Boccia; Roberta Siliquini; Walter Ricciardi; Paolo Villari Journal: PLoS One Date: 2015-06-10 Impact factor: 3.240
Authors: Allison M Glasser; Caroline O Cobb; Lyubov Teplitskaya; Ollie Ganz; Lauren Katz; Shyanika W Rose; Shari Feirman; Andrea C Villanti Journal: BMJ Open Date: 2015-04-29 Impact factor: 2.692